{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:04Z","timestamp":1791357184924,"version":"4.3.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T00:00:00Z","timestamp":1411689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T00:00:00Z","timestamp":1411689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/npp.2014.261","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T06:57:58Z","timestamp":1411714678000},"page":"259-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?"],"prefix":"10.1038","volume":"40","author":[{"given":"Gerard","family":"Sanacora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F","family":"Schatzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,26]]},"reference":[{"key":"BFnpp2014261_CR1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","volume":"67","author":"M aan het Rot","year":"2010","unstructured":"aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS et al (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67: 139\u2013145.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","volume":"72","author":"M Aan Het Rot","year":"2012","unstructured":"Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012). Ketamine for depression: where do we go from here? Biol Psychiatry 72: 537\u2013547.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","volume":"79","author":"NA Anis","year":"1983","unstructured":"Anis NA, Berry SC, Burton NR, Lodge D (1983). The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79: 565\u2013575.","journal-title":"Br J Pharmacol"},{"key":"BFnpp2014261_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91\u201395.","journal-title":"Nature"},{"key":"BFnpp2014261_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/sj.npp.1300158","volume":"28","author":"CG Bachmann","year":"2003","unstructured":"Bachmann CG, Linthorst AC, Holsboer F, Reul JM (2003). Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 28: 1056\u20131067.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2014261_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0006-3223(02)01432-4","volume":"52","author":"JK Belanoff","year":"2002","unstructured":"Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C et al (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52: 386\u2013392.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR7","doi-asserted-by":"crossref","unstructured":"Belujon P, Grace AA (2014). Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. Biol Psychiatry (e-pub ahead of print).","DOI":"10.1016\/j.biopsych.2014.04.014"},{"key":"BFnpp2014261_CR8","first-page":"10","volume":"46","author":"SA Bergman","year":"1999","unstructured":"Bergman SA (1999). Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 46: 10\u201320.","journal-title":"Anesth Prog"},{"key":"BFnpp2014261_CR9","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.biopsych.2012.02.039","volume":"72","author":"P Blier","year":"2012","unstructured":"Blier P, Zigman D, Blier J (2012). On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry 72: e11\u2013e12.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR10","unstructured":"Burch R (2012). A phase 2, randomized single blind, single intravenous dose of GLYX-12, an NMDA receptor glycine site functional partial agonist, in subjects with major depressive disorder with inadequate response to antidepressant medication. 51st Annual Meeting, American College of Neuropyschopharmacology, 2012; Hollywood, FL, USA."},{"key":"BFnpp2014261_CR11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.biopsych.2011.11.006","volume":"71","author":"GM Chowdhury","year":"2012","unstructured":"Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G (2012). (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry 71: 1022\u20131025.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR12","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/npp.2014.26","volume":"39","author":"N Dawson","year":"2014","unstructured":"Dawson N, McDonald M, Higham DJ, Morris BJ, Pratt JA (2014). Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks. Neuropsychopharmacology 39: 1786\u20131798.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2014261_CR13","unstructured":"DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C et al (2014). In vivo ketamine-induced changes in [C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry (e-pub ahead of print)."},{"key":"BFnpp2014261_CR14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","volume":"71","author":"N DiazGranados","year":"2010","unstructured":"DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA et al (2010). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71: 1605\u20131611.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2014261_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/mp.2012.194","volume":"18","author":"NR Driesen","year":"2013","unstructured":"Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC et al (2013). Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry 18: 1199\u20131204.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2014261_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.1222939","volume":"338","author":"RS Duman","year":"2012","unstructured":"Duman RS, Aghajanian GK (2012). Synaptic dysfunction in depression: potential therapeutic targets. Science 338: 68\u201372.","journal-title":"Science"},{"key":"BFnpp2014261_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1017\/S1461145711001702","volume":"15","author":"JM Dwyer","year":"2012","unstructured":"Dwyer JM, Lepack AE, Duman RS (2012). mTOR activation is required for the antidepressant effects of mGluR(2)\/(3) blockade. Int J Neuropsychopharmacol 15: 429\u2013434.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFnpp2014261_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1124\/mol.113.089334","volume":"84","author":"CM Emnett","year":"2013","unstructured":"Emnett CM, Eisenman LN, Taylor AM, Izumi Y, Zorumski CF, Mennerick S (2013). Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Mol Pharmacol 84: 935\u2013947.","journal-title":"Mol Pharmacol"},{"key":"BFnpp2014261_CR19","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s00213-013-3378-0","volume":"231","author":"K Fukumoto","year":"2014","unstructured":"Fukumoto K, Iijima M, Chaki S (2014). Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2\/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology 231: 2291\u20132298.","journal-title":"Psychopharmacology"},{"key":"BFnpp2014261_CR20","doi-asserted-by":"publisher","first-page":"8649","DOI":"10.1073\/pnas.1323920111","volume":"111","author":"ES Gideons","year":"2014","unstructured":"Gideons ES, Kavalali ET, Monteggia LM (2014). Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA 111: 8649\u20138654.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2014261_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","volume":"119","author":"A Gupta","year":"2011","unstructured":"Gupta A, Devi LA, Gomes I (2011). Potentiation of mu-opioid receptor-mediated signaling by ketamine. J Neurochem 119: 294\u2013302.","journal-title":"J Neurochem"},{"key":"BFnpp2014261_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrn2911","volume":"11","author":"GE Hardingham","year":"2010","unstructured":"Hardingham GE, Bading H (2010). Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11: 682\u2013696.","journal-title":"Nat Rev Neurosci"},{"key":"BFnpp2014261_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1017\/S1461145712000910","volume":"16","author":"U Heresco-Levy","year":"2013","unstructured":"Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC et al (2013). A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 16: 501\u2013506.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFnpp2014261_CR24","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1007\/s00213-014-3451-3","volume":"231","author":"TM Hillhouse","year":"2014","unstructured":"Hillhouse TM, Porter JH, Negus SS (2014). Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology 231: 2705\u20132716.","journal-title":"Psychopharmacology"},{"key":"BFnpp2014261_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1124\/jpet.113.207522","volume":"347","author":"T Hiranita","year":"2013","unstructured":"Hiranita T, Soto PL, Tanda G, Kopajtic TA, Katz JL (2013). Stimulants as specific inducers of dopamine-independent sigma agonist self-administration in rats. J Pharmacol Exp Ther 347: 20\u201329.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2014261_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/npp.2009.168","volume":"35","author":"LE Hong","year":"2010","unstructured":"Hong LE, Summerfelt A, Buchanan RW, O'Donnell P, Thaker GK, Weiler MA et al (2010). Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 35: 632\u2013640.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2014261_CR27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","volume":"74","author":"CC Huang","year":"2013","unstructured":"Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P et al (2013). Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 74: 734\u2013741.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR28","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.4088\/JCP.11r07485","volume":"73","author":"N Iovieno","year":"2012","unstructured":"Iovieno N, Papakostas GI (2012). Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry 73: 1300\u20131306.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2014261_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.brainres.2005.02.032","volume":"1042","author":"J Karasawa","year":"2005","unstructured":"Karasawa J, Shimazaki T, Kawashima N, Chaki S (2005). AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 1042: 92\u201398.","journal-title":"Brain Res"},{"key":"BFnpp2014261_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejphar.2011.04.022","volume":"661","author":"O Kekesi","year":"2011","unstructured":"Kekesi O, Tuboly G, Szucs M, Birkas E, Morvay Z, Benedek G et al (2011). Long-lasting, distinct changes in central opioid receptor and urinary bladder functions in models of schizophrenia in rats. Eur J Pharmacol 661: 35\u201341.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2014261_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cns.12081","volume":"19","author":"B Kocsis","year":"2013","unstructured":"Kocsis B, Brown RE, McCarley RW, Hajos M (2013). Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. CNS Neurosci Ther 19: 437\u2013447.","journal-title":"CNS Neurosci Ther"},{"key":"BFnpp2014261_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","volume":"224","author":"H Koike","year":"2011","unstructured":"Koike H, Iijima M, Chaki S (2011). Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224: 107\u2013111.","journal-title":"Behav Brain Res"},{"key":"BFnpp2014261_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4088\/JCP.v66n0312","volume":"66","author":"LM Koran","year":"2005","unstructured":"Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M (2005). Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 66: 353\u2013359.","journal-title":"J Clin Psychiatry"},{"issue":"Pt 19","key":"BFnpp2014261_CR34","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1113\/jphysiol.2009.176297","volume":"587","author":"SE Kotermanski","year":"2009","unstructured":"Kotermanski SE, Wood JT, Johnson JW (2009). Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J Physiol 587 (Pt 19): 4589\u20134604.","journal-title":"J Physiol"},{"key":"BFnpp2014261_CR35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","volume":"73","author":"JH Krystal","year":"2013","unstructured":"Krystal JH, Sanacora G, Duman RS (2013). Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73: 1133\u20131141.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR36","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.biopsych.2012.05.031","volume":"72","author":"G Laje","year":"2012","unstructured":"Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N et al (2012). Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72: e27\u2013e28.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR37","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959\u2013964.","journal-title":"Science"},{"key":"BFnpp2014261_CR38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","volume":"69","author":"N Li","year":"2011","unstructured":"Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H et al (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754\u2013761.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.biopsych.2010.08.030","volume":"69","author":"Y Liao","year":"2011","unstructured":"Liao Y, Tang J, Corlett PR, Wang X, Yang M, Chen H et al (2011). Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry 69: 42\u201348.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pnpbp.2013.04.017","volume":"45","author":"JM Lima-Ojeda","year":"2013","unstructured":"Lima-Ojeda JM, Vogt MA, Pfeiffer N, Dormann C, Kohr G, Sprengel R et al (2013). Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuropsychopharmacol Biol Psychiatry 45: 28\u201333.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFnpp2014261_CR41","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.biopsych.2011.09.030","volume":"71","author":"RJ Liu","year":"2012","unstructured":"Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK (2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 71: 996\u20131005.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR42","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/bdi.12003","volume":"14","author":"DA Luckenbaugh","year":"2012","unstructured":"Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA et al (2012). Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord 14: 880\u2013887.","journal-title":"Bipolar Disord"},{"key":"BFnpp2014261_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","volume":"159","author":"DA Luckenbaugh","year":"2014","unstructured":"Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE et al (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 159: 56\u201361.","journal-title":"J Affect Disord"},{"key":"BFnpp2014261_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","volume":"63","author":"S Maeng","year":"2008","unstructured":"Maeng S, Zarate CA Jr ., Du J, Schloesser RJ, McCammon J, Chen G et al (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349\u2013352.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR45","first-page":"1","volume":"10","author":"A McGirr","year":"2014","unstructured":"McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2014). A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 10: 1\u201312.","journal-title":"Psychol Med"},{"key":"BFnpp2014261_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0960327111417908","volume":"31","author":"AK Mehta","year":"2012","unstructured":"Mehta AK, Halder S, Khanna N, Tandon OP, Sharma KK (2012). Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: role of opioid and N-methyl-D-aspartate receptors. Hum Exp Toxicol 31: 51\u201356.","journal-title":"Hum Exp Toxicol"},{"key":"BFnpp2014261_CR47","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/cns.12099","volume":"19","author":"G Mion","year":"2013","unstructured":"Mion G, Villevieille T (2013). Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 19: 370\u2013380.","journal-title":"CNS Neurosci Ther"},{"key":"BFnpp2014261_CR48","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921\u20132927.","journal-title":"J Neurosci"},{"key":"BFnpp2014261_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1254\/jphs.12R08CP","volume":"120","author":"T Mori","year":"2012","unstructured":"Mori T, Yoshizawa K, Shibasaki M, Suzuki T (2012). Discriminative stimulus effects of hallucinogenic drugs: a possible relation to reinforcing and aversive effects. J Pharmacol Sci 120: 70\u201376.","journal-title":"J Pharmacol Sci"},{"key":"BFnpp2014261_CR50","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170: 1134\u20131142.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2014261_CR51","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M et al (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250\u2013256.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","volume":"210","author":"CL Nemeth","year":"2010","unstructured":"Nemeth CL, Paine TA, Rittiner JE, Beguin C, Carroll FI, Roth BL et al (2010). Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology 210: 263\u2013274.","journal-title":"Psychopharmacology"},{"key":"BFnpp2014261_CR53","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1017\/S1461145714000649","volume":"17","author":"N Nishitani","year":"2014","unstructured":"Nishitani N, Nagayasu K, Asaoka N, Yamashiro M, Shirakawa H, Nakagawa T et al (2014). Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex. Int J Neuropsychopharmacology 17: 1321\u20131326.","journal-title":"Int J Neuropsychopharmacology"},{"key":"BFnpp2014261_CR54","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","volume":"33","author":"E Nosyreva","year":"2013","unstructured":"Nosyreva E, Szabla K, Autry AE, Ryazanov AG, Monteggia LM, Kavalali ET (2013). Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 33: 6990\u20137002.","journal-title":"J Neurosci"},{"key":"BFnpp2014261_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0006-8993(95)00057-W","volume":"675","author":"G Nowak","year":"1995","unstructured":"Nowak G, Ordway GA, Paul IA (1995). Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 675: 157\u2013164.","journal-title":"Brain Res"},{"key":"BFnpp2014261_CR56","first-page":"365","volume":"50","author":"G Nowak","year":"1998","unstructured":"Nowak G, Ossowska G, Jopek R, Papp M (1998). Strychnine-insensitive glycine\/NMDA sites are altered in two stress models of depression. Pol J Pharmacol 50: 365\u2013369.","journal-title":"Pol J Pharmacol"},{"key":"BFnpp2014261_CR57","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0022-3565(25)38235-2","volume":"265","author":"G Nowak","year":"1993","unstructured":"Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA (1993). Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 265: 1380\u20131386.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2014261_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","volume":"1562","author":"F Pacheco Dda","year":"2014","unstructured":"Pacheco Dda F, Romero TR, Duarte ID (2014). Central antinociception induced by ketamine is mediated by endogenous opioids and mu- and delta-opioid receptors. Brain Res 1562: 69\u201375.","journal-title":"Brain Res"},{"key":"BFnpp2014261_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(94)90516-9","volume":"263","author":"M Papp","year":"1994","unstructured":"Papp M, Moryl E (1994). Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 263: 1\u20137.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2014261_CR60","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","volume":"82","author":"MP Parsons","year":"2014","unstructured":"Parsons MP, Raymond LA (2014). Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82: 279\u2013293.","journal-title":"Neuron"},{"key":"BFnpp2014261_CR61","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al (2007). Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102\u20131107.","journal-title":"Nat Med"},{"key":"BFnpp2014261_CR62","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0922-4106(93)90199-J","volume":"247","author":"IA Paul","year":"1993","unstructured":"Paul IA, Layer RT, Skolnick P, Nowak G (1993). Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur J Pharmacol 247: 305\u2013311.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2014261_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00213-007-0706-2","volume":"192","author":"EB Perry Jr","year":"2007","unstructured":"Perry EB Jr, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A et al (2007). Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 192: 253\u2013260.","journal-title":"Psychopharmacology"},{"key":"BFnpp2014261_CR64","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","volume":"65","author":"LE Phelps","year":"2009","unstructured":"Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr (2009). Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 65: 181\u2013184.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR65","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.biopsych.2013.01.021","volume":"73","author":"A Pilc","year":"2013","unstructured":"Pilc A, Wieronska JM, Skolnick P (2013). Glutamate-based antidepressants: preclinical psychopharmacology. Biol Psychiatry 73: 1125\u20131132.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn3138","volume":"13","author":"M Popoli","year":"2012","unstructured":"Popoli M, Yan Z, McEwen BS, Sanacora G (2012). The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13: 22\u201337.","journal-title":"Nat Rev Neurosci"},{"key":"BFnpp2014261_CR67","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","volume":"28","author":"SH Preskorn","year":"2008","unstructured":"Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101\u2009606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28: 631\u2013637.","journal-title":"J Clin Psychopharmacol"},{"key":"BFnpp2014261_CR68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/da.22253","volume":"31","author":"RB Price","year":"2014","unstructured":"Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ et al (2014). Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 31: 335\u2013343.","journal-title":"Depress Anxiety"},{"key":"BFnpp2014261_CR69","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.euroneuro.2011.08.002","volume":"22","author":"MJ Robson","year":"2012","unstructured":"Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2012). Evaluation of sigma (sigma) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol 22: 308\u2013317.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFnpp2014261_CR70","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D et al (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38: 2475\u20132483.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2014261_CR71","unstructured":"Sanacora G, Johnson M, Khan A, Atkinson S, Riesenberg R, Schronen J et al (2014). Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebocontrolled study (PURSUIT). Presented at the American Society of Clinical Psychiatry; Hollywood, FL, USA."},{"key":"BFnpp2014261_CR72","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/mp.2013.130","volume":"19","author":"G Sanacora","year":"2013","unstructured":"Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ et al (2013). Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19: 978\u2013985.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2014261_CR73","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","volume":"26","author":"G Sani","year":"2012","unstructured":"Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G et al (2012). The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 26: 663\u2013690.","journal-title":"CNS Drugs"},{"key":"BFnpp2014261_CR74","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1176\/appi.ajp.2014.13101434","volume":"171","author":"AF Schatzberg","year":"2014","unstructured":"Schatzberg AF (2014). A word to the wise about ketamine. Am J Psychiatry 171: 262\u2013264.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2014261_CR75","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","volume":"78","author":"SA Schobel","year":"2013","unstructured":"Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I et al (2013). Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 78: 81\u201393.","journal-title":"Neuron"},{"key":"BFnpp2014261_CR76","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jcph.122","volume":"53","author":"F Segmiller","year":"2013","unstructured":"Segmiller F, Ruther T, Linhardt A, Padberg F, Berger M, Pogarell O et al (2013). Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 53: 996\u2013998.","journal-title":"J Clin Pharmacol"},{"key":"BFnpp2014261_CR77","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1017\/S1461145714001011","volume":"17","author":"PR Shiroma","year":"2014","unstructured":"Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO (2014). Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17: 1805\u20131813.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFnpp2014261_CR78","unstructured":"Singh J (2014). A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of intravenous ketamine in patients with treatment-resistant depression. Presented at the American Society for Clinical Psychopharmacology. Hollywood, FL, USA."},{"key":"BFnpp2014261_CR79","doi-asserted-by":"crossref","unstructured":"Sinner B, Graf BM (2008). Ketamine. Handb Exp Pharmacol 313\u2013333.","DOI":"10.1007\/978-3-540-74806-9_15"},{"key":"BFnpp2014261_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0014-2999(99)00330-1","volume":"375","author":"P Skolnick","year":"1999","unstructured":"Skolnick P (1999). Antidepressants for the new millennium. Eur J Pharmacol 375: 31\u201340.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2014261_CR81","doi-asserted-by":"publisher","first-page":"966","DOI":"10.4088\/JCP.12m08252","volume":"74","author":"EG Smith","year":"2013","unstructured":"Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ (2013). Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 74: 966\u2013973.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2014261_CR82","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","volume":"150","author":"VL Stauffer","year":"2013","unstructured":"Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP et al (2013). Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 150: 434\u2013441.","journal-title":"Schizophr Res"},{"key":"BFnpp2014261_CR83","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ajem.2007.12.005","volume":"26","author":"RJ Strayer","year":"2008","unstructured":"Strayer RJ, Nelson LS (2008). Adverse events associated with ketamine for procedural sedation in adults. Am J Emer Med 26: 985\u20131028.","journal-title":"Am J Emer Med"},{"key":"BFnpp2014261_CR84","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-2999(99)00762-1","volume":"385","author":"T Suzuki","year":"1999","unstructured":"Suzuki T, Aoki T, Kato H, Yamazaki M, Misawa M (1999). Effects of the 5-HT(3) receptor antagonist ondansetron on the ketamine- and dizocilpine-induced place preferences in mice. Eur J Pharmacol 385: 99\u2013102.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2014261_CR85","doi-asserted-by":"crossref","unstructured":"Tam YH, Ng CF, Pang KK, Yee CH, Chu WC, Leung VY et al (2014). One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients' characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. BJU Int (e-pub ahead of print).","DOI":"10.1111\/bju.12675"},{"key":"BFnpp2014261_CR86","doi-asserted-by":"publisher","first-page":"e43947","DOI":"10.1371\/journal.pone.0043947","volume":"7","author":"S Tan","year":"2012","unstructured":"Tan S, Lam WP, Wai MS, Yu WH, Yew DT (2012). Chronic ketamine administration modulates midbrain dopamine system in mice. PLoS One 7: e43947.","journal-title":"PLoS One"},{"key":"BFnpp2014261_CR87","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/313479a0","volume":"313","author":"AM Thomson","year":"1985","unstructured":"Thomson AM, West DC, Lodge D (1985). An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313: 479\u2013481.","journal-title":"Nature"},{"key":"BFnpp2014261_CR88","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/npp.2013.71","volume":"38","author":"AK Walker","year":"2013","unstructured":"Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B et al (2013). NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL\/6J mice. Neuropsychopharmacology 38: 1609\u20131616.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2014261_CR89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fnana.2013.00023","volume":"7","author":"C Wang","year":"2013","unstructured":"Wang C, Zheng D, Xu J, Lam W, Yew DT (2013). Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat 7: 23.","journal-title":"Front Neuroanat"},{"key":"BFnpp2014261_CR90","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/add.12228","volume":"108","author":"D Wood","year":"2013","unstructured":"Wood D (2013). Ketamine and damage to the urinary tract. Addiction 108: 1515\u20131516.","journal-title":"Addiction"},{"key":"BFnpp2014261_CR91","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00213-014-3543-0","volume":"231","author":"C Yang","year":"2014","unstructured":"Yang C, Hashimoto K (2014). Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231: 2041\u20132042.","journal-title":"Psychopharmacology"},{"key":"BFnpp2014261_CR92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","volume":"74","author":"CA Zarate Jr.","year":"2013","unstructured":"Zarate CA Jr., Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I et al (2013). A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74: 257\u2013264.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2014261_CR93","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006a). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856\u2013864.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2014261_CR94","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","volume":"163","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate CA Jr., Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA et al (2006b). A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163: 153\u2013155.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2014261_CR95","doi-asserted-by":"publisher","first-page":"24151","DOI":"10.1074\/jbc.M113.482000","volume":"288","author":"X Zhou","year":"2013","unstructured":"Zhou X, Ding Q, Chen Z, Yun H, Wang H (2013). Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic N-methyl-D-aspartate receptor function and neuronal excitotoxicity. J Biol Chem 288: 24151\u201324159.","journal-title":"J Biol Chem"}],"updated-by":[{"DOI":"10.1038\/npp.2014.338","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2014261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2014261","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2014261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T17:04:15Z","timestamp":1746378255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2014261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,26]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFnpp2014261"],"URL":"https:\/\/doi.org\/10.1038\/npp.2014.261","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,26]]},"assertion":[{"value":"30 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}